Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862

NCT01473108 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Clinical Pharmacology

Interventions

DRUG: Finerenone (BAY 94-8862) PEG solution
DRUG: Finerenone (BAY 94-8862) immediate release tablet
DRUG: Eplerenone (Inspra®)
DRUG: Placebo

Sponsor

Bayer